Utilizing TAS-102 and Regorafenib for Future Studies

Dr. Wafik El-Deiry of Brown University continues his discussion of regorafenib plus TAS-102 for colorectal cancer, focusing on the potential use of this combination in future gastrointestinal cancer studies.

He also expands on how the combination reduces ALDH1 expression in HT29 cells, and the benefits of targeting ERK1/2 and STAT3 activation.

Watch the first part of our interview with Dr. El-Deiry here.

00:00 Synergy in Liver Cancer Cells

01:43 Inducing ALDH1a Expression in HT29 Cells

05:27 The Benefits of Inhibiting ERK1/2 and STAT3 Activation

06:57 Future Studies Planned